the Scientists presented preliminary results of the first randomized, placebo-controlled study of the experimental antiviral drug in patients ramdevpir COVID-19. Drug with direct action, which the experts had high hopes, and journalists have touted almost as a panacea against the new coronavirus, has shown efficacy only slightly better than placebo.
the researchers ‘ Conclusions: hospitalized patients with progressive lesion COVID-19 and lung damage treated with ramdevpir, recovered faster than patients in similar condition who received placebo.
But a breakthrough drug at the time established for the treatment of Ebola, did not.
Average recovery time for patients who daily for 10 days were given injections of ramdevpir was 11 days compared with 15 days for those who received a placebo. The mortality rate was 8.0 per cent for the treated group ramdevpir, compared to 11.6% for the placebo group.
However, the FDA (management under the control over products and medicines of the USA) is in talks with the manufacturer of the drug about how to make ramdevpir available to patients as quickly as possible.
Definitive conclusions about the effectiveness and safety of ramdevpir will be made later. From Italy, in particular, came reports about the development in some patients who were treated with redecision. Serious complications of the cardiovascular system.
Clinical studies are ongoing in 47 hospitals in the United States and in 21 countries in Europe and Asia.
